A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors

Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, SunYoung Rha, Hyuncheol Chung, Joseph P. Eder, Sunil Sharma, Yung Jue Bang, Jeffrey R. InfanteLi Yan, Johann S. De Bono, Hendrik Tobias Arkenau

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The PI3K/protein kinase B (AKT) pathway Results: A total of 65 patients were enrolled; dose-limiting is commonly activated in several tumor types. Selective toxicities were hypophosphatemia and hypocalcemia. Adverse targeting of p110b could result in successful pathway inhibi-events included diarrhea (48%), nausea (40%), and vomiting tion while avoiding the on- and off-target effects of pan-PI3K (31%). Single- and repeat-dose exposure increased generally dose inhibitors. GSK2636771 is a potent, orally bioavailable, proportionally. GSK2636771 400 mg once daily was the RP2D. adenosine triphosphate-competitive, selective inhibitor of Phospho/total AKT ratio decreased with GSK2636771 in tumor PI3Kb. and surrogate tissue. A castrate-resistant prostate cancer (CRPC) Methods: We evaluated the safety, pharmacokinetics, phar-patient harboring PIK3CB amplification had a partial response for macodynamics and antitumor activity of GSK2636771 to over a year; an additional 10 patients derived durable (24 define the recommended phase II dose (RP2D). During the weeks) clinical benefit, including two other patients with CRPC dose-selection and dose-escalation stages (parts 1 and 2), with PIK3CB alterations (34 weeks). GSK2636771 400 mg patients with PTEN-deficient advanced solid tumors received once daily orally induced sufficient exposure and target inhibition escalating doses of GSK2636771 (25–500 mg once daily) using with a manageable safety profile. a modified 3þ3 design to determine the RP2D; tumor type-Conclusions: Genomic aberrations of PIK3CB may be associ-specific expansion cohorts (part 3) were implemented to fur-ated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); ther assess tumor responses at the RP2D. 5981–92. 2017 AACR.

Original languageEnglish
Pages (from-to)5981-5992
Number of pages12
JournalClinical Cancer Research
Volume23
Issue number19
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

1-Phosphatidylinositol 4-Kinase
Neoplasms
Phosphatidylinositol 3-Kinases
Prostatic Neoplasms
Hypophosphatemia
Safety
Proto-Oncogene Proteins c-akt
Hypocalcemia
Nausea
Vomiting
Diarrhea
Pharmacokinetics
Adenosine Triphosphate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mateo, Joaquin ; Ganji, Gopinath ; Lemech, Charlotte ; Burris, Howard A. ; Han, Sae Won ; Swales, Karen ; Decordova, Shaun ; DeYoung, M. Phillip ; Smith, Deborah A. ; Kalyana-Sundaram, Shanker ; Wu, Jiuhua ; Motwani, Monica ; Kumar, Rakesh ; Tolson, Jerry M. ; Rha, SunYoung ; Chung, Hyuncheol ; Eder, Joseph P. ; Sharma, Sunil ; Bang, Yung Jue ; Infante, Jeffrey R. ; Yan, Li ; De Bono, Johann S. ; Arkenau, Hendrik Tobias. / A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 19. pp. 5981-5992.
@article{5306ad195ba942f4a848f4d7649a095b,
title = "A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors",
abstract = "Background: The PI3K/protein kinase B (AKT) pathway Results: A total of 65 patients were enrolled; dose-limiting is commonly activated in several tumor types. Selective toxicities were hypophosphatemia and hypocalcemia. Adverse targeting of p110b could result in successful pathway inhibi-events included diarrhea (48{\%}), nausea (40{\%}), and vomiting tion while avoiding the on- and off-target effects of pan-PI3K (31{\%}). Single- and repeat-dose exposure increased generally dose inhibitors. GSK2636771 is a potent, orally bioavailable, proportionally. GSK2636771 400 mg once daily was the RP2D. adenosine triphosphate-competitive, selective inhibitor of Phospho/total AKT ratio decreased with GSK2636771 in tumor PI3Kb. and surrogate tissue. A castrate-resistant prostate cancer (CRPC) Methods: We evaluated the safety, pharmacokinetics, phar-patient harboring PIK3CB amplification had a partial response for macodynamics and antitumor activity of GSK2636771 to over a year; an additional 10 patients derived durable (24 define the recommended phase II dose (RP2D). During the weeks) clinical benefit, including two other patients with CRPC dose-selection and dose-escalation stages (parts 1 and 2), with PIK3CB alterations (34 weeks). GSK2636771 400 mg patients with PTEN-deficient advanced solid tumors received once daily orally induced sufficient exposure and target inhibition escalating doses of GSK2636771 (25–500 mg once daily) using with a manageable safety profile. a modified 3{\th}3 design to determine the RP2D; tumor type-Conclusions: Genomic aberrations of PIK3CB may be associ-specific expansion cohorts (part 3) were implemented to fur-ated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); ther assess tumor responses at the RP2D. 5981–92. 2017 AACR.",
author = "Joaquin Mateo and Gopinath Ganji and Charlotte Lemech and Burris, {Howard A.} and Han, {Sae Won} and Karen Swales and Shaun Decordova and DeYoung, {M. Phillip} and Smith, {Deborah A.} and Shanker Kalyana-Sundaram and Jiuhua Wu and Monica Motwani and Rakesh Kumar and Tolson, {Jerry M.} and SunYoung Rha and Hyuncheol Chung and Eder, {Joseph P.} and Sunil Sharma and Bang, {Yung Jue} and Infante, {Jeffrey R.} and Li Yan and {De Bono}, {Johann S.} and Arkenau, {Hendrik Tobias}",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-17-0725",
language = "English",
volume = "23",
pages = "5981--5992",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

Mateo, J, Ganji, G, Lemech, C, Burris, HA, Han, SW, Swales, K, Decordova, S, DeYoung, MP, Smith, DA, Kalyana-Sundaram, S, Wu, J, Motwani, M, Kumar, R, Tolson, JM, Rha, S, Chung, H, Eder, JP, Sharma, S, Bang, YJ, Infante, JR, Yan, L, De Bono, JS & Arkenau, HT 2017, 'A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors', Clinical Cancer Research, vol. 23, no. 19, pp. 5981-5992. https://doi.org/10.1158/1078-0432.CCR-17-0725

A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. / Mateo, Joaquin; Ganji, Gopinath; Lemech, Charlotte; Burris, Howard A.; Han, Sae Won; Swales, Karen; Decordova, Shaun; DeYoung, M. Phillip; Smith, Deborah A.; Kalyana-Sundaram, Shanker; Wu, Jiuhua; Motwani, Monica; Kumar, Rakesh; Tolson, Jerry M.; Rha, SunYoung; Chung, Hyuncheol; Eder, Joseph P.; Sharma, Sunil; Bang, Yung Jue; Infante, Jeffrey R.; Yan, Li; De Bono, Johann S.; Arkenau, Hendrik Tobias.

In: Clinical Cancer Research, Vol. 23, No. 19, 01.10.2017, p. 5981-5992.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors

AU - Mateo, Joaquin

AU - Ganji, Gopinath

AU - Lemech, Charlotte

AU - Burris, Howard A.

AU - Han, Sae Won

AU - Swales, Karen

AU - Decordova, Shaun

AU - DeYoung, M. Phillip

AU - Smith, Deborah A.

AU - Kalyana-Sundaram, Shanker

AU - Wu, Jiuhua

AU - Motwani, Monica

AU - Kumar, Rakesh

AU - Tolson, Jerry M.

AU - Rha, SunYoung

AU - Chung, Hyuncheol

AU - Eder, Joseph P.

AU - Sharma, Sunil

AU - Bang, Yung Jue

AU - Infante, Jeffrey R.

AU - Yan, Li

AU - De Bono, Johann S.

AU - Arkenau, Hendrik Tobias

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: The PI3K/protein kinase B (AKT) pathway Results: A total of 65 patients were enrolled; dose-limiting is commonly activated in several tumor types. Selective toxicities were hypophosphatemia and hypocalcemia. Adverse targeting of p110b could result in successful pathway inhibi-events included diarrhea (48%), nausea (40%), and vomiting tion while avoiding the on- and off-target effects of pan-PI3K (31%). Single- and repeat-dose exposure increased generally dose inhibitors. GSK2636771 is a potent, orally bioavailable, proportionally. GSK2636771 400 mg once daily was the RP2D. adenosine triphosphate-competitive, selective inhibitor of Phospho/total AKT ratio decreased with GSK2636771 in tumor PI3Kb. and surrogate tissue. A castrate-resistant prostate cancer (CRPC) Methods: We evaluated the safety, pharmacokinetics, phar-patient harboring PIK3CB amplification had a partial response for macodynamics and antitumor activity of GSK2636771 to over a year; an additional 10 patients derived durable (24 define the recommended phase II dose (RP2D). During the weeks) clinical benefit, including two other patients with CRPC dose-selection and dose-escalation stages (parts 1 and 2), with PIK3CB alterations (34 weeks). GSK2636771 400 mg patients with PTEN-deficient advanced solid tumors received once daily orally induced sufficient exposure and target inhibition escalating doses of GSK2636771 (25–500 mg once daily) using with a manageable safety profile. a modified 3þ3 design to determine the RP2D; tumor type-Conclusions: Genomic aberrations of PIK3CB may be associ-specific expansion cohorts (part 3) were implemented to fur-ated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); ther assess tumor responses at the RP2D. 5981–92. 2017 AACR.

AB - Background: The PI3K/protein kinase B (AKT) pathway Results: A total of 65 patients were enrolled; dose-limiting is commonly activated in several tumor types. Selective toxicities were hypophosphatemia and hypocalcemia. Adverse targeting of p110b could result in successful pathway inhibi-events included diarrhea (48%), nausea (40%), and vomiting tion while avoiding the on- and off-target effects of pan-PI3K (31%). Single- and repeat-dose exposure increased generally dose inhibitors. GSK2636771 is a potent, orally bioavailable, proportionally. GSK2636771 400 mg once daily was the RP2D. adenosine triphosphate-competitive, selective inhibitor of Phospho/total AKT ratio decreased with GSK2636771 in tumor PI3Kb. and surrogate tissue. A castrate-resistant prostate cancer (CRPC) Methods: We evaluated the safety, pharmacokinetics, phar-patient harboring PIK3CB amplification had a partial response for macodynamics and antitumor activity of GSK2636771 to over a year; an additional 10 patients derived durable (24 define the recommended phase II dose (RP2D). During the weeks) clinical benefit, including two other patients with CRPC dose-selection and dose-escalation stages (parts 1 and 2), with PIK3CB alterations (34 weeks). GSK2636771 400 mg patients with PTEN-deficient advanced solid tumors received once daily orally induced sufficient exposure and target inhibition escalating doses of GSK2636771 (25–500 mg once daily) using with a manageable safety profile. a modified 3þ3 design to determine the RP2D; tumor type-Conclusions: Genomic aberrations of PIK3CB may be associ-specific expansion cohorts (part 3) were implemented to fur-ated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); ther assess tumor responses at the RP2D. 5981–92. 2017 AACR.

UR - http://www.scopus.com/inward/record.url?scp=85032305458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032305458&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-0725

DO - 10.1158/1078-0432.CCR-17-0725

M3 - Article

C2 - 28645941

AN - SCOPUS:85032305458

VL - 23

SP - 5981

EP - 5992

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -